References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2025-33-45-52

medalphabet-4838

Research Article

Статьи

Деэскалация системной терапии раннего и местно-распространенного тройного негативного рака молочной железы

De-escalation of systemic therapy for early and locally advanced triple negative breast cancer

https://orcid.org/0000-0001-5505-037X

Ратова

Е. И.

Ratova

E. I.

Ратова Евгения Игоревна, аспирант отделения химиотерапии отдела лекарственного лечения опухолей

Web of Science ResearcherID: MDS-7101–2025

Москва

Ratova Evgeniya I., postgraduate student at Chemotherapy Dept, Dept of Drug Treatment of Tumors

Web of Science ResearcherID: MDS-7101-2025

Moscow

ratovaevgenia@yandex.ru

Савчина

В. В.

Savchina

V. V.

Савчина Виктория Владимировна, научный сотрудник отделения химиотерапии отдела лекарственного лечения опухолей

Москва

Savchina Victoria V., researcher at Chemotherapy Dept, Dept of Drug Treatment of Tumors

Moscow

https://orcid.org/0000-0003-4879-2687

Болотина

Л. В.

Bolotina

L. V.

Болотина Лариса Владимировна, д. м. н., заведующая отделением химиотерапии отдела лекарственного лечения опухолей

Author ID (Scopus): 594953.

Москва

Bolotina Larisa V., Dr Med Sci (habil.), head of Chemotherapy Dept, Dept of Drug Treatment of Tumors

Author ID (Scopus): 594953

Moscow

https://orcid.org/0000-0001-8784-8415

Каприн

А. Д.

Kaprin

A. D.

Каприн Андрей Дмитриевич, д. м. н., профессор, академик РАН, академик РАО, генеральный директор, директор МНИОИ им. П. А. Герцена – филиала; заведующий кафедрой онкологии и рентгенорадиологии им. академика РАН В. П. Харченко

Author ID (Scopus): 96775.

Москва

Kaprin Andrey D., Dr Med Sci (habil.), professor, RAS academician, academician of the Russian Academy of Education, general director, director of P. A. Herzen Moscow Research Institute of Oncology – branch, head of V. P. Kharchenko Dept of Oncology and Roentgenology

Author ID (Scopus): 96775

Moscow

ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРоссияNational Medical Research Radiological CentreRussian Federation

ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России; ФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»РоссияNational Medical Research Radiological Centre; Peoples’ Friendship University of Russia named after Patrice LumumbaRussian Federation

2025

21012026

033

«Диагностика и онкотерапия» (4)

4552

2026

Ратова Е.И., Савчина В.В., Болотина Л.В., Каприн А.Д.

Ratova E.I., Savchina V.V., Bolotina L.V., Kaprin A.D.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/4838

Неоадъювантная химиотерапия (НАХТ) раннего и местно-распространенного тройного негативного рака молочной железы (ТНРМЖ) является обязательным звеном в составе радикального лечения. Достижение полного патоморфологического регресса (пПР) определяет прогноз заболевания, позволяет провести органосохраняющее лечение, а также снижает риск рецидива и улучшает общую выживаемость. В последнее время наблюдается увеличение количества исследований, направленных на интенсификацию НАХТ, что объясняется известной агрессивностью данного подтипа рака молочной железы. Однако, увеличение частоты и тяжести нежелательных явлений, часто нивелирующих улучшение эффекта лечения, привели к появлению исследований, направленных на снижение химиотерапевтической нагрузки НАХТ ТНРМЖ без потери его эффективности. Изучаемые схемы химиотерапии могут стать новыми стандартами неоадъювантного этапа комплексного лечения резектабельных форм ТНРМЖ. В этом обзоре рассмотрен текущий стандарт системного лечения раннего и местно-распространенного ТНРМЖ, а также возможные варианты деэскалации лекарственной терапии.

Neoadjuvant chemotherapy (NACT) for early and locally advanced triple negative breast cancer (TNBC) is a mandatory component of radical treatment. Achieving complete pathomorphological regress determines prognosis of the disease, allows for organ-preserving treatment, and also reduces the risk of recurrence and improves overall survival. Recently, there has been an increase number of studies aimed at intensifying NACT, which is explained by the well-known aggressiveness of this subtype of breast cancer. However, an increase frequency and severity of adverse events, which often offset the improvement in the effect of treatment, led to the emergence of studies aimed at reducing the chemotherapeutic burden of NACT breast cancer without losing its effectiveness. The studied chemotherapy regimens may become new standards for the neoadjuvant stage of complex treatment of resectable breast cancer. This review examines the current standard of systemic treatment for early and locally advanced breast cancer, as well as possible options for de-escalation of drug therapy.

тройной негативный рак молочной железыплатиносодержащая неоадъювантная химиотерапиядеэскалация неоадъювантной химиотерапииBRCA-ассоциированный тройной негативный рак молочной железы

triple negative breast cancerplatinum-containing neoadjuvant chemotherapyde-escalation of neoadjuvant chemotherapyBRCA-associated triple negative breast cancer

References1

Cancer Today [Electronic resource]. URL: https://gco.iarc.who.int/today/en/dataviz/pie?mode=cancer&group_populations=1&types=1&populations=900&-sexes=2

S SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [updated: 2024 Nov 5; cited 2025 Jan 29]. Available from: https://seer.cancer.gov/statistics-network/explorer/. Data source(s): SEER Incidence Data, November 2023 Submission (1975–2021), SEER 22 registries [Electronic resource]. URL: https://seer.cancer.gov/statistics-network/explorer/application.html?site=623&-data_type=4&graph_type=5&compareBy=stage&chk_stage_104=104&chk_stage_105=105&series=9&hdn_sex=3&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0.

Rebecca Dent; Maureen Trudeau; Kathleen I. Pritchard et al. Triple-negative breast cancer: clinical features and patterns of recurrence // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007. Vol. 13, № 15 Pt 1. P. 4429–4434. DOI: 10.1158/1078–0432.CCR-06–3045. URL: https://aacrjournals.org/clincancerres/article/13/15/4429/194334/Triple-Negative-Breast-Cancer-Clinical-Features

Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer | Journal of Clinical Oncology 2008. Vol. 26, № 8. DOI: 10.1200/JCO.2007.14.4147 [Electronic resource]. URL: https://ascopubs.org/doi/10.1200/JCO.2007.14.4147?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

Norman Wolmark, Jiping Wang, Eleftherios Mamounas. et al. Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18 // JNCI Monogr. 2001. Vol. 2001, № 30. P. 96–102. DOI: 10.1093/oxfordjournals.jncimonographs.a003469. URL: https://academic.oup.com/jncimono/article/2001/30/96/936263?login=true.

C. E. Geyer, W. M. Sikov, J. Huober. et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial // Ann. Oncol. Elsevier, 2022. Vol. 33, № 4. P. 384–394. DOI: 10.1016/j.annonc.2022.01.009. URL: https://www.sciencedirect.com/science/article/pii/S0923753422000187?via%3Dihub.

Prof Sibylle Loibl MD, Joyce O’Shaughnessy MD, Prof Michael Untch MD. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighT-Ness): a randomised, phase 3 trial // Lancet Oncol. Elsevier, 2018. Vol. 19, № 4. P. 497–509. DOI: 10.1016/S1470–2045(18)30111-6. URL: https://www.sciencedirect.com/science/article/abs/pii/S1470204518301116?via%3Dihub.

Hermela Shimelis, Holly LaDuca, Chunling Hu. et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing | JNCI: Journal of the National Cancer Institute | Oxford Academic, 2018. Vol. 110, № 8. P. 855–862. DOI: 10.1093/jnci/djy106. URL: https://academic.oup.com/jnci/article/110/8/855/5062996?login=false.

Amanda B Spurdle, Fergus J Couch, Michael T Parsons. et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 16, 3419 (2014). DOI: 10.1186/s13058–014–0474-y. URL: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0474-y.

T. Byrski, T. Huzarski, R. Dent. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients // Breast Cancer Res. Treat. 2009. Vol. 115, № 2. P. 359–363. DOI: 10.1007/s10549-008-0128-9. URL: https://link.springer.com/article/10.1007/s10549-008-0128-9.

Daniel P. Silver, Andrea L. Richardson, Aron C. Eklund. et al. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer // J. Clin. Oncol. Wolters Kluwer, 2010. Vol. 28, № 7. P. 1145–1153. DOI: 10.1200/JCO.2009.22.4725. URL: https://ascopubs.org/doi/10.1200/JCO.2009.22.4725?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

William M. Sikov, Don S. Dizon, Rochelle Strenger. et al. Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study | Journal of Clinical Oncology, 2009. Vol. 27, № 28. URL: https://ascopubs.org/doi/10.1200/JCO.2008.21.4163?url_ver=Z39.88-2003&r-fr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

William M. Sikov, Donald A. Berry, Charles M. Perou. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) // J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015. Vol. 33, № 1. P. 13–21. DOI: 10.1200/JCO.2014.57.0572. URL: https://ascopubs.org/doi/10.1200/JCO.2014.57.0572?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&r-fr_dat=cr_pub%20%200pubmed.

Prof Gunter von Minckwitz MD, Prof Andreas Schneeweiss MD, Prof Sibylle Loibl MD. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial – The Lancet Oncology, 2014. Vol. 15, № 7. P. 747–756. DOI: 10.1016/S1470–2045(14)70160-3. URL: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70160-3/abstract.

Masashi Ando, Hideko Yamauchi, Kenjiro Aogi. et al. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment, 2014. Vol. 145. P. 401–409. DOI: 10.1007/s10549-014-2947-1 URL: https://link.springer.com/article/10.1007/s10549-014-2947-1.

Eric Hahnen, Ph D. Bianca Lederer, Ph D. Jan Hauke, Ph D. et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial // JAMA Oncol. 2017. Vol. 3, № 10. P. 1378–1385. DOI: 10.1001/jamaoncol.2017.1007. URL: https://jamanetwork.com/journals/jamaoncology/fullarticle/2643514.

F. Poggio. M. Bruzzone. M. Ceppi. et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of Oncology, 2018. Vol. 29, № 7. P. 1497–1508. DOI: 10.1093/annonc/mdy127. URL: https://www.annalsofoncology.org/article/S0923-7534(19)32098-8/fulltext#secst0080.

F. Poggio. M. Tagliamento. M. Ceppi. et al. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate // Ann. Oncol. Elsevier, 2022. Vol. 33, № 3. P. 347–349. DOI: 10.1016/j.annonc.2021.11.016. URL: https://www.sciencedirect.com/science/article/pii/S0923753421048316?via%3Dihub.

Gupta S. Nair NS. Hawaldar RW. et al. Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6–10, 2022; San Antonio, TX. Abstract GS 5–01.

P. Schmid. J. Cortés. R. A. Dent. et al. LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study // Ann. Oncol. 2023. Vol. 34. P. S 1257. DOI: 10.1016/j.annonc.2023.10.008. URL: https://www.sciencedirect.com/science/article/pii/S0923753423041522?via%3Dihub.

Loibl S. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up // Ann. Oncol. Elsevier, 2024. Vol. 35, № 2. P. 159–182.

NSABP Foundation Inc. A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo: Clinical trial registration NCT03281954. clinicaltrials.gov, 2024. SABCS 2024.

Charles E. Geyer, Sibylle Loibl, Priya Rastogi. et al. NSABP B-59/GBG 96-Gepar-Douze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. // J. Clin. Oncol. American Society of Clinical Oncology, 2019. Vol. 37, № 15. DOI: 10.1200/JCO.2019.37.15_suppl.TPS605. URL: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS605.

Swain S. M., Whaley F. S., Ewer M. S. Congestive heart failure in patients treated with doxorubicin, 2003. Vol. 97, № 11. DOI: 10.1002/cncr.11407. URL: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.11407.

Geoffrey Bostany, BA, Yanjun Chen, MS, Liton Francisco, BA. et al. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors. Journal of Clinical Oncology, 2025. Vol. 43, № 1. P. 32–45. DOI: 10.1200/JCO.23.01779. URL: https://ascopubs.org/doi/10.1200/JCO.23.01779.

Stephen Jones Steve. Frankie Ann Holmes. Joyce O’Shaughnessy. et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology, 2009. Vol. 27, № 8. P. 1177–1183. DOI: 10.1200/JCO.2008.18.4028. URL: https://ascopubs.org/doi/10.1200/JCO.2008.18.4028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

Ulrike Nitz, MD. Oleg Gluz, MD. Michael Clemens, MD. et al. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer // J. Clin. Oncol. Wolters Kluwer, 2019. Vol. 37, № 10. P. 799–808. DOI: 10.1200/JCO.18.00028. URL: https://ascopubs.org/doi/10.1200/JCO.18.00028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&r-fr_dat=cr_pub%20%200pubmed.

Sofia Re Mason. Melina L Willson. Sam J Egger. et al. Platinum chemotherapy for early triple-negative breast cancer // Breast Edinb. Scotl. 2024. Vol. 75. P. 103712. DOI: 10.1016/j.breast.2024.103712. URL: https://www.sciencedirect.com/science/article/pii/S0960977624000432?via%3Dihub.

Pin Zhang1. Yi Yin. Hongnan Mo. et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial // Oncotarget. 2016. Vol. 7, № 37. P. 60647–60656. DOI: 10.18632/oncotarget.10607. URL: https://www.oncotarget.com/article/10607/text/.

Liulu Zhang, Zhi-Yong Wu, Jie Li. et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial // Int. J. Cancer. 2022. Vol. 150, № 4. P. 654–662. DOI: 10.1002/ijc.33830. URL: https://onlinelibrary.wiley.com/doi/10.1002/ijc.33830.

Priyanka Sharma; Bruce F. Kimler. Anne O’Dea. et al. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP) // Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021. Vol. 27, № 4. P. 975–982. DOI: 10.1158/1078–0432.CCR-20–3646. URL: https://aacrjournals.org/clincancerres/article/27/4/975/125183/Randomized-Phase-II-Trial-of-Anthracycline-free.

О. О. Гордеева. И. В. Колядина. Л. Г. Жукова et al. Эффективность и безопасность неоадъювантной химиотерапии в режиме PlaTax у больных трижды негативным раком молочной железы II–III стадий. Опухоли женской репродуктивной системы, 2020. Vol. 16, № 2. DOI: 10.17650/1994-4098-2020-16-2-25-37. URL: https://cyberleninka.ru/article/n/effektivnost-i-bezopasnost-neoadyuvantnoy-himioterapii-v-rezhime-platax-u-bolnyh-trizhdy-negativnym-rakom-molochnoy-zhelezy-ii-iii/viewer

Andrew Tutt. Holly Tovey. Maggie Chon U. Cheang. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 2018. Vol. 24. P. 628–637. DOI: 10.1038/s41591-018-0009-7. URL: https://www.nature.com/articles/s41591-018-0009-7?error=cookies_not_supported&code=012e3d9b-de01-4f5d-ab67-60343f10d4f8.

Priyanka Sharma, MD 1. Shane R. Stecklein, MD, Ph D. Rachel Yoder, MS. et al. Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial // JAMA Oncol. 2024. Vol. 10, № 2. P. 227–235. DOI: 10.1001/jamaoncol.2023.5033. URL: https://jamanetwork.com/journals/jamaoncology/fullarticle/2812294

The authors declare that there are no conflicts of interest present.